Urogen Pharma LTD Form 4 insider transactions

UroGen Pharma Ltd. Director Leana Wen acquired 10,000 stock options and 8,000 restricted stock units, signaling continued confidence in the company.

UroGen Pharma Ltd. Director and 10% owner Arie Belldegrun acquired 20,000 stock options with an exercise price of $19.5.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has filed a Form 4 indicating a future sale of 10,000 ordinary shares at an average price of $17.69, effective August 11, 2025.

UroGen Pharma Ltd.'s CEO, Elizabeth A. Barrett, was granted 87,615 performance stock units (PSUs) following the achievement of a corporate milestone.

UroGen Pharma's General Counsel, Jason Drew Smith, reported the vesting of 16,500 performance stock units and the subsequent sale of 7,522 shares to cover tax obligations.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, reported the acquisition of shares from vested performance units and a subsequent sale to cover tax obligations.

UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, reported the acquisition of 10,000 ordinary shares from vested restricted stock units and the subsequent sale of 5,162 shares to cover tax obligations.

Chief Medical Officer Mark Schoenberg reports acquisition and disposal of UroGen Pharma shares and restricted stock units on January 31, 2025.

Jason Drew Smith, General Counsel of UroGen Pharma, reports acquisition and disposal of ordinary shares and restricted stock units to cover withholding tax obligations.

UroGen Pharma's CEO, Elizabeth A. Barrett, was granted 96,377 restricted stock units (RSUs) on January 31, 2025, according to a Form 4 filing with the SEC.

Chris Degnan, CFO of UroGen Pharma Ltd., reports acquisition of restricted stock units and stock options.

Chief Medical Officer Mark Schoenberg reports acquisition and disposal of UroGen Pharma shares related to restricted stock units.

Jason Smith, General Counsel of UroGen Pharma Ltd., reports the acquisition and disposal of ordinary shares and restricted stock units.

Chief Financial Officer Dong Kim reports acquiring 2,500 ordinary shares of UroGen Pharma Ltd. through the vesting of restricted stock units.

A Form 4 filing reveals that UroGen Pharma Ltd. director Arie Belldegrun acquired 10,000 stock options on August 6, 2024.

Director Fred E. Cohen acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.

Director Daniel George Wildman acquired stock options for 10,000 UroGen Pharma Ltd. shares on August 6, 2024.

Director Stuart Holden acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.

Director James A. Robinson Jr. acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.

Director Leana Wen acquired stock options for 10,000 UroGen Pharma Ltd. ordinary shares on August 6, 2024.

Director Cynthia M Butitta acquired 10,000 stock options in UroGen Pharma Ltd on August 6, 2024.

Chief Medical Officer Mark Schoenberg sold shares of UroGen Pharma to cover withholding tax obligations following the vesting of restricted stock units.

Chief Medical Officer of UroGen Pharma, Mark Schoenberg, sold 12,000 ordinary shares on March 18, 2024.